Table 1 Demographic and clinical characteristics of the study population
From: Predicting progression to severe COVID-19 using the PAINT score
| Characteristic | All patients (n = 239) | Without progression (n = 216) | Progression to severe (n = 23) | p value |
|---|---|---|---|---|
| Sex Male n (%) | 139 (58.2) | 130 (60.2) | 9 (39.1) | 0.038 |
| Age (year) | 58 (26–90) | 57.5 (26–88) | 62 (29–90) | 0.010 |
| Max temperature (℃) | 38.0 (36.0–41.0) | 38.0 (36.0–39.8) | 38.3 (36.5–41.0) | 0.129 |
| Clinical manifestations, n (%) | ||||
| Fever | 186 (77.8) | 168 (77.8) | 18 (78.3) | 0.688 |
| Cough | 144 (60.3) | 127 (58.8) | 17 (73.9) | 0.175 |
| Expectoration | 57 (23.8) | 50 (23.1) | 7 (30.4) | 0.642 |
| Dyspnea | 25 (10.5) | 23 (10.7) | 2 (8.7) | 0.001 |
| Chest pain | 11 (4.6) | 10 (4.6) | 1 (4.3) | 0.982 |
| Angina | 10 (4.2) | 8 (3.7) | 2 (8.7) | 0.662 |
| Fatigue | 68 (28.5) | 58 (26.9) | 10 (43.5) | 0.206 |
| Myalgia | 22 (9.2) | 22 (10.2) | 0 | 0.221 |
| Headache | 12 (5.0) | 12 (5.6) | 0 | 0.476 |
| Vomit | 4 (1.7) | 3 (1.4) | 1 (4.3) | 0.421 |
| Diarrhea | 43 (18.0) | 40 (18.5) | 3 (13.0) | 0.787 |
| Comorbidities, n (%) | ||||
| Hypertension | 66 (27.6) | 60 (27.8) | 6 (26.1) | 0.782 |
| Diabetes mellitus | 25 (10.5) | 20 (9.3) | 5 (21.7) | 0.285 |
| Cardiac disease | 20 (8.4) | 19 (8.8) | 1 (4.3) | 0.509 |
| Pulmonary disease | 10 (4.2) | 7 (3.2) | 3 (13.0) | 0.035 |
| Liver disease | 11 (4.6) | 8 (3.7) | 3 (13.0) | 0.027 |